First Time Loading...

Chinook Therapeutics Inc
NASDAQ:KDNY

Watchlist Manager
Chinook Therapeutics Inc Logo
Chinook Therapeutics Inc
NASDAQ:KDNY
Watchlist
Price: 40.39 USD
Updated: Apr 29, 2024
Section:
 

Wall Street
Price Targets

KDNY Price Targets Summary
Chinook Therapeutics Inc

Wall Street analysts forecast KDNY stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for KDNY is 40 USD .

KDNY Lowest Forecast
Wall Street Target
Not Available
KDNY Average Forecast
Wall Street Target
40 USD
1% Downside
KDNY Highest Forecast
Wall Street Target
Not Available
Lowest
Price Target
Not Available
Average
Price Target
40 USD
1% Downside
Highest
Price Target
Not Available
Chinook Therapeutics Inc Competitors:
Price Targets
PHARM
Pharming Group NV
106% Upside
BIOCON
Biocon Ltd
6% Downside
QNCX
Quince Therapeutics Inc
183% Upside
ZYME
Zymeworks Inc
81% Upside
PHARM
Pharming Group NV
106% Upside
BIOCON
Biocon Ltd
6% Downside
QNCX
Quince Therapeutics Inc
183% Upside
ZYME
Zymeworks Inc
81% Upside
AGEN
Agenus Inc
52% Downside
AURA
Aura Biosciences Inc
180% Upside
S
688293
Shanghai OPM Biosciences Co Ltd
43% Upside
D
002030
Daan Gene Co Ltd
91% Upside

Revenue
Forecast

Revenue Estimate
Chinook Therapeutics Inc

For the last 8 years the compound annual growth rate for Chinook Therapeutics Inc's revenue is -9%. The projected CAGR for the next 3 years is 137%.

-9%
Past Growth
137%
Estimated Growth
Estimates Accuracy
-3%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Chinook Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-5%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Chinook Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-75%
Average Miss
What are analyst estimates?

See Also

Summary
KDNY intrinsic value, competitors valuation, and company profile.
DCF Valuation
KDNY stock valuation using Discount Cash Flow valuation method.
Relative Valuation
KDNY stock valuation using valuation multiples.
Wall Street Estimates
KDNY price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
KDNY stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is KDNY's stock price target?
Price Target
40 USD

According to Wall Street analysts, the average 1-year price target for KDNY is 40 USD .

What is Chinook Therapeutics Inc's Revenue forecast?
Projected CAGR
137%

For the last 8 years the compound annual growth rate for Chinook Therapeutics Inc's revenue is -9%. The projected CAGR for the next 3 years is 137%.

ALPHA SPREAD
Join more than 132,500+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.